Double Trouble: Interrupting DAPT and COVID-19


Author(s):

Theofana Mihăilă1,2, Aurelian Roșca1,2, Bianca Ion1

Affiliation:

1 “George Emil Palade” University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, Romania
2 Clinic of Cardiology, Emergency Clinical County Hospital, Târgu Mureș, Romania

DOI: 10.2478/jce-2022-0007

ABSTRACT
Cardiovascular disorders have been described as relevant risk factor for severe COVID infection. Stent thrombosis is a life-threatening complication that may occur subacutely. We present an interesting case of a middle-aged woman who developed acute stent thrombosis while interrupting dual antiplatelet therapy (DAPT) ticagrelor, during an episode of coronavirus disease (COVID-19). In our case, the patient’s not-compliance to DAPT, associated with COVID-19 infection and a hyperinflammatory and hypercoagulable state associated with it played a major role in the development of stent thrombosis. The hypercoagulable and hyperinflammatory state associated with COVID-19 has important implications for cardiac patients, especially those undergoing complex coronary intervention, predisposing them to an increased risk of post-PCI complications.